Back to Search Start Over

Epinephrine in anaphylaxis: too little, too late.

Authors :
Lieberman JA
Wang J
Source :
Current opinion in allergy and clinical immunology [Curr Opin Allergy Clin Immunol] 2020 Oct; Vol. 20 (5), pp. 452-458.
Publication Year :
2020

Abstract

Purpose of Review: Epinephrine is the agreed-upon first line treatment for anaphylaxis, yet it continues to be underused by patients/caregivers and providers alike.<br />Recent Findings: There are unfortunately limited data on how epinephrine can best be utilized in anaphylaxis, which hinders how best to inform patients and providers. Studies reporting underuse suggest various barriers and themes on why this may happen.<br />Summary: Continued education of patients, caregivers, and providers is needed; however, is not likely to be enough to close the gap. Thus, novel studies on how to increase use; increase availability in a cost-effective manner; and newer, effective delivery routes are still needed.

Details

Language :
English
ISSN :
1473-6322
Volume :
20
Issue :
5
Database :
MEDLINE
Journal :
Current opinion in allergy and clinical immunology
Publication Type :
Academic Journal
Accession number :
32739981
Full Text :
https://doi.org/10.1097/ACI.0000000000000680